Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib in Recurrent Glioblastoma or Anaplastic Glioma
NCT02345824Phase 1Unknown
- Sponsor
- University of Virginia
- Start
- Mar 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribociclib in glioblastoma (GBM) and anaplastic glioma, sponsored by University of Virginia. Primary endpoint: Inhibition of CDK4/CDK6 Signaling Pathway in Cell Proliferation at 1 year. Status: unknown.
02
Drugs
ribociclib
03
Conditions
glioblastoma (GBM)anaplastic glioma
Beyond the preview
Go deeper on NCT02345824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345824.